Compare ERNA & GP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ERNA | GP |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 6.4M |
| IPO Year | 2021 | 2013 |
| Metric | ERNA | GP |
|---|---|---|
| Price | $10.82 | $1.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 149.9K |
| Earning Date | 05-07-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $582,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $0.23 |
| 52 Week High | $15.88 | $4.00 |
| Indicator | ERNA | GP |
|---|---|---|
| Relative Strength Index (RSI) | 62.49 | 59.58 |
| Support Level | $0.61 | $0.88 |
| Resistance Level | $15.88 | $1.17 |
| Average True Range (ATR) | 2.48 | 0.06 |
| MACD | -0.21 | -0.00 |
| Stochastic Oscillator | 46.03 | 53.13 |
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.